An anti-fibrotic microRNA, AFM-1000, for the therapy of pulmonary fibrosis
This invention includes ananti-fibrotic therapy that effectively reduces pulmonary fibrosis. In an in vitro fibroblast culture system, an in vivo bleomycin-induced pulmonaryfibrosis in mice and lung tissues from IPF patients, it was discovered that theexpression of a number of microRNAs were down-regulated in all three models.Adenovirus-mediated expression of a specific down regulated microRNA attenuatedlung fibrosis and improved lung function in a bleomycin mouse model. Theseresults suggested that upregulating this microRNA may be a potentialtherapeutic for IPF.
Anti-fibrotic therapyTargets multiple pathwaysAttenuates fibrosis in mouse model
Therapeutic forpulmonary fibrosisTherapeutic forother fibrotic diseases
None
美国
